AKBA vs. VTYX, RAPT, NKTR, XERS, PYXS, HOWL, INZY, VNDA, VSTM, and NBTX
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Ventyx Biosciences (VTYX), RAPT Therapeutics (RAPT), Nektar Therapeutics (NKTR), Xeris Biopharma (XERS), Pyxis Oncology (PYXS), Werewolf Therapeutics (HOWL), Inozyme Pharma (INZY), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Akebia Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 264.96%. Ventyx Biosciences has a consensus target price of $21.75, suggesting a potential upside of 348.45%. Given Ventyx Biosciences' higher probable upside, analysts clearly believe Ventyx Biosciences is more favorable than Akebia Therapeutics.
In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 7 articles in the media. Akebia Therapeutics' average media sentiment score of 0.50 beat Ventyx Biosciences' score of 0.10 indicating that Akebia Therapeutics is being referred to more favorably in the media.
Akebia Therapeutics has higher revenue and earnings than Ventyx Biosciences. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Ventyx Biosciences has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -26.32%. Akebia Therapeutics' return on equity of 0.00% beat Ventyx Biosciences' return on equity.
Akebia Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 3.8% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Akebia Therapeutics received 383 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 63.96% of users gave Akebia Therapeutics an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
Summary
Akebia Therapeutics beats Ventyx Biosciences on 10 of the 16 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
